Kent, United Kingdom

Ian Osterloh

USPTO Granted Patents = 89 

 

 

Average Co-Inventor Count = 5.0

ph-index = 31

Forward Citations = 3,566(Granted Patents)


Inventors with similar research interests:


Company Filing History:


Years Active: 2012-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Triglycerides
Cardiovascular Disease
Mixed Dyslipidemia
Hypertriglyceridemia
Apolipoprotein C-III
High-Sensitivity C-Reactive Protein
Pharmaceutical Compositions
EPA
LDL-C Levels
Stable Pharmaceutical Composition
Fish Allergy
Endometrium Dislocation
89 patents (USPTO):Explore Patents

Title: Ian Osterloh: A Pioneer in the Pharmaceutical Industry

Introduction:

Throughout his remarkable career, Ian Osterloh has made significant contributions to the pharmaceutical industry, playing a pivotal role in the development of life-saving medications. With an impressive portfolio of patents and an unwavering commitment to innovation, Osterloh has undoubtedly left an indelible mark on the field of healthcare.

Latest Patents:

Ian Osterloh's latest patents include a groundbreaking invention called the "Low Eructation Composition and Methods for Treating and/or Preventing Cardiovascular Disease in a Subject with Fish Allergy/Hypersensitivity." This innovative pharmaceutical composition and treatment method have promising applications in managing cardiovascular-related diseases. The patent highlights Osterloh's dedication to improving patient care and addressing specific healthcare challenges.

Career Highlights:

With a total of 88 patents to his name, Ian Osterloh has an exceptional record of accomplishments. His expertise lies in the pharmaceutical domain, where he has consistently strived to develop novel approaches to combat various health conditions. Through his inventive work, Osterloh has significantly contributed to the advancement of medical science, making a positive impact on countless lives.

Collaborations:

During his career, Osterloh has collaborated with esteemed organizations in the pharmaceutical industry, including companies like Amarin Pharmaceuticals Ireland Limited and Preglem SA. These collaborations have allowed him to leverage his expertise in multidisciplinary projects, fostering innovation and the development of novel solutions to pressing healthcare challenges.

Among his notable colleagues and collaborators are Pierre Wicker and Paresh Soni. Through teamwork and shared vision, Osterloh has demonstrated his ability to forge strong partnerships and achieve collective success.

Conclusion:

Ian Osterloh's accomplishments in the pharmaceutical industry are nothing short of extraordinary. His plethora of patents, including the recent invention for treating cardiovascular-related diseases, reflects his unyielding dedication to improving human health and well-being.

As an esteemed figure in the field, Osterloh continues to inspire future generations of inventors and researchers. His innovative mindset, coupled with his collaborative nature, sets an example for aspiring scientists who aspire to make a lasting impact on the healthcare landscape.

With each milestone achieved, Ian Osterloh propels the pharmaceutical industry forward, leaving no doubt that his legacy will continue to shape the future of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…